natgillin/translations-raw huggingface dataset:
The composition of claim 1, wherein said porogen hydrogel or said bulk hydrogel or both hydrogels recruit a cell into the composition. 
Pripravak u skladu s patentnim zahtjevom 1, naznačen time što navedeni porogeni hidrogel ili navedeni volumni hidrogel ili oba hidrogela novače stanicu u pripravak.
Torsional asymmetry due to restricted rotation about an asymmetric single bond, for example because of steric hindrance or ring strain, may permit separation of different conformers. 
Torzijska asimetrija zbog ograničene rotacije oko asimetrične jednostruke veze, primjerice zbog steričkog ometanja ili napona prstena, može omogućiti razdvajanje različitih konformera.
More particularly, before the filling step, the method according to the invention comprises a first preparation step, in which first holes 5 for connecting the cavity 1 to the outside (FIG. 1) are formed in the region of the mass of soil or of the body in general which is comprised between the cavity 1 and a working surface 10 located outside the mass of soil or the body in general. 
- prvi pripremni korak, prilikom kojega se naprave prve rupe (5) za spajanje šupljine (1) na vanjski dio, u području gomile zemlje ili tijela općenito zbijenom između šupljine (1) i radne površine (10) smještene izvan gomile zemlje ili građenog tijela općenito;
The solid oral extended release pharmaceutical dosage form of claim 1, wherein the extended release matrix formulation after having been stored at 25 °C and 60 % relative humidity (RH) for at least 1 month provides a dissolution rate, when measured in a USP Apparatus 1 (basket) at 100 rpm in 900 ml simulated gastric fluid without enzymes (SGF) at 37° C, characterized by the percent amount of active agent released at 1, 4 and 12 hours of dissolution that deviates no more than about 15 % points from the corresponding in-vitro dissolution rate of a reference formulation prior to storage. 
Oralni farmaceutski oblik doziranja u krutom stanju sa produljenim otpuštanjem prema bilo kojem od zahtjeva 1 do pri čemu formulacija matrice sa produljenim otpuštanjem nakon što je pohranjena na 25 *C 1 60 % relativne vlažnosti (RH) tijekom najmanje 1 mjeseca daje brzinu otapanja, koja kada je mjerena na USP aparatu 1 (košara) kod 100 okr/min. u 900 ml simulirane želučane tekućine bez enzima (SGF) na 37? C, naznačen time da postotak količine oslobođenog aktivnog sredstva kod 1,4 1 12 sati otapanja nema odstupanje veće od oko 15 % točaka u odnosu na odgovarajuću in-vitro brzinu otapanja referentne formulacije prije skladištenja.
Example 26. A device according to example 25, wherein said lens is disposable (onetime use). 
Uređaj u skladu s patentnim zahtjevom 26, kod kojega se navedena leća može odbaciti (za jednokratnu upotrebu).
A 9- cis- retinal derivative having a structure represented by Formula I wherein A is CH2OR and R forms a retinyl ester, for use in the treatment of an endogenous 11- cis -retinal deficiency in a human subject. 
Derivat 9-cis-retinala čija je struktura predstavljena Formulom I, [image] naznačen time, da A predstavlja CH2OR, a R tvori retinil ester namijenjen liječenju endogena deficijencija 11-cis-retinala kod ljudskog subjekta.
A pharmaceutical aerosol solution composition according to any one of claims 1 to 15 wherein the overall formoterol degradation products level is lower than 2% w/w with respect to the theoretical formoterol fumarate content of 6mcg/actuation and the residual level of the formoterol fumarate is higher than 95% w/w with respect to its initial content. 
Farmaceutski pripravak aerosolne otopine prema patentnom zahtjevu 13 u kojem je ukupna razina degradacijskog produkta formoterola niža od 2% w/w prema teorijskom sadržaju formoterol-fumarata od 6 ug/aktiviranju, a preostala razina formoterol-fumarata je viša od 95% w/w prema njegovom početnom sadržaju.
The apparatus of claim 4, wherein the L1 signaling data includes notch width information indicating a width of a notch band existing in the signal frame. 
Uređaj iz patentnog zahtjeva 4, pri čemu signalni podatak L1 uključuje informaciju širine obilježja koja ukazuje širinu polja obilježja koje postoji u okviru signala,
An isolated antibody or antigen-binding fragment thereof that specifically binds to a lysyl oxidase-like 2 (LOXL2) protein, wherein the antibody or fragment is a non-competitive inhibitor of LOXL2. 
Izolirano protutijelo ili njegov za antigen vezni fragment koji se veže za lizil oksidaza-sličan (LOXL2) protein, pri čemu se to protutijelo ili antigen vezni fragment specifično vežu za aminokiselinsku sekvencu SEQ ID NO:6 i inhibiraju enzimatsku aktivnost proteina LOXL2, pri čemu je inhibicija ne-kompetitivna.
For example, the method may further comprise administering a psychiatric drug to the subject in combination with the administering of d-methadone. 
D-metadon za uporabu prema zahtjevu 1, naznačen time što se psihijatrijski lijek daje subjektu u kombinaciji s d-metadonom.
The immunogenic composition of any preceding claim wherein the same carrier protein is used in the Hib conjugate and the or each of the at least one N. meningitidis saccharide conjugate(s). 
Imunogeni pripravak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što isti proteinski nosač se upotrebljava u konjugatu Hib i u dva ili više od najmanje dva dodatna konjugata bakterijskih saharida.
65 mm. With use of such a pump portion 2b, the internal pressure of the developer supply container 1 (developer accommodating portion 2 and discharging portion 3h) higher than the ambient pressure and the internal pressure lower than the ambient pressure are produced alternately and repeatedly at a predetermined cyclic period (approx. 
Spremnik za nadopunjavanje razvijača u skladu s patentnim zahtjevima 1 ili 2, naznačen time što navedeni dio za pretvorbu pogona (2d, 3b) pretvara silu vrtnje na takav način da se unutarnji tlak u navedenoj komori za ispuštanje Tazvijača (3h) mijenja između tlaka nižeg od tlaka okoliša i tlaka višeg od tlaka okoliša.
The compound of claim 1 wherein the compounds is or a stereoisomer or pharmaceutically acceptable salt thereof. 
CECI TA HR P20110373 TI ili stereoizomer ili njegova farmaceutski prihvatljiva sol.
The results obtained are represented in Tables 6a and 6b. 
Dobijeni rezultati su predstavljeni u Tabelama 6a i 6b.
the third stream decompressed by the decompressing means is in a gas-liquid mixed state and both of a gas component and a liquid component of the third stream are returned to the storage tank (11). 
Sustav za obradu ukapljenog plina u skladu s patentnim zahtjevom 2, naznačen time što se treću struju, dekomprimiranu u plinsko-tekuće miješano stanje, vraća u spremnik za teret (11).
Concerning the properties of said veneer according to the invention, also reference is made to the hitherto description, and it is explicitly made reference thereto. 
Å to se tiče svojstava navedenog furnira koji je u skladu s ovim izumom, također se poziva na opis koji se nalazi ovdje i izričito se poziva na njega.
The compound of claim 4 wherein A1 is phenyl, pyridinyl, indazolyl, indolyl, benzoimidazolyl, pyrrolopyridinyl or pyrrolopyrimidinyl; each optionally substituted with one methyl, methoxy, methylamino or dimethylamino; or a pharmaceutically acceptable salt thereof. 
Spoj u skladu s patentnim zahtjevom 4, naznačen time što je A1 fenil, piridinil, indazolil, indolil, benzoimidazolil, pirolopiridinil ili pirolopirimidinil; gdje je svaki od njih može biti supstituiran s jednim metilom, metoksi, metilamino ili dimetilamino; ili njegova farmaceutski prihvatljiva sol.
Alternatively the aminocrotonate (III), ketoester (IV) and aldehyde can be heated together in the solvent. 
Alternativno 5 se aminokrotonat (III), ketoester (IV) i aldehid mogu zajednički zagrijavati u otapalu.
It has surprisingly been found that the polymorphic form of venlafaxine hydrochloride is not changed in the process of the present invention, even if water containing suspensions are used for applying the sustained release polymer or for the application of the separating layer. 
Iznenađujuće je opaženo da se polimorfni oblik venlafaksin-hidroklorida ne mijenja u postupku prema ovom izumu, čak i ako se za primjenu polimera za produljeno otpuštanje ili separacijskog sloja upotrebljava suspenzije koje sadrže vodu.
A compound, which is 3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile, or a pharmaceutically acceptable salt thereof, for use in treating a cancer selected from acute lymphoblastic leukemia, cancer of the head and neck, gastric cancer, glioblastoma, melanoma, Sezary syndrome, and mycosis fungoides in a patient. 
Farmaceutski sastav koji sadrži spoj koji je 3-ciklopentil-3-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]propannitril; ili njegovu farmaceutski prihvatljivu sol; i farmaceutski prihvatljiv nosač; pri čemu je navedeni sastav pogodan za oralnu primjenu i za osiguravanje produženog oslobađanja navedenog spoja ili navedene soli.
reacting an intermediate of formula (II) with H—R2a or with a suitable salt form of H—R2a, optionally in the presence of a suitable solvent and optionally in the presence of a suitable base 
Postupak za pripremu spoja prema patentnom zahtjevu 1, naznačen time da gadrži a) reakciju intermedijera formule (II) sa H-R* ili sa pogodnim oblikom soli od H-R, po izboru u prisutnosti pogodnog otapala i po izboru u prisutnosti pogodne baze
In one embodiment, the product is for use in the treatment of infertility in a patient having serum AMH level of 15 to 24.9 pmol/L, and the product is to be administered at a daily dose of 0.14 to 0.19 µg human derived recombinant FSH (preferably 0.15 to 0.16 µg human derived recombinant FSH) per kg bodyweight of the patient. 
PATENTNI ZAHTJEVI Proizvod koji sadrži rekombinantni ljudski folikulostimulirajući hormon (FSH) za upotrebu u liječenju neplodnosti kod pacijenta koji ima razinu serum AMH <15 pmol/L, naznačen time da se proizvod daje u dozi od, ili ekvivalentnoj 11-13 ug rekombinantnog ljudskog FSH na dan, 12 do 16 dana nakon primjene GnRH agonista.
controlling the support device so as to obtain a desired deformed shape of the mould area, 
- > nadziranje suportivne naprave (5) za dobivanje željenog deformiranog oblika područja kalupa (3),
In certain aspects, HIV titer in the subject infected with HIV is decreased after contacting the subject with the isolated polypeptide. 
Uporaba u skladu s patentnim zahtjevom 1, naznačena time što so HIV titar kod subjekta inficiranog HIV-om smanjuje nakon kontaktiranja subjekta s izoliranim polipeptidom.
Further disclosure regarding these nozzle arrangements can be found in International Patent Application Publications WO 94/07607 A1 and WO 99/16530 A1. 
Daljnji opis što se tiče ovih naprava s mlaznicom može se naći u WO 94/07607 A1 i WO 99/16530 A1.
The binder according to claim 8, wherein the non-hydraulically reactive material is selected from the group consisting of ground limestone/dolomite, precipitated CaCO3, Ca(OH)2, Mg(OH)2, silica fume and glass powder, contained in a range of 5 to 20% by weight. 
Vezivo sukladno barem jednom od zahtjeva 3 do 6, naznačeno time što dodatno sadrži hidraulički reaktivne materijale, poput Portland cementa i/ili ne hidraulički reaktivne materijale, poput mljevenog vapnenca/dolomita, istaloženog CaCO:s, Ca(OH) 2, Me(OH) 2, silikonskog dima raspona od 1 do 30 % mase, poželjno od 5 do 20 % mase.
The composition of claim 22, wherein the composition is in the form of a tablet, capsule, powder, pellet, suspension, emulsion, cream, gel, ointment, lotion, or paste. 
Farmaceutski pripravak u skladu s patentnim zahtjevom 19, naznačen time što je navedeni pripravak u obliku tablete, kapsule, praška, peleta, suspenzije, emulzije, kreme, gela, masti ili paste.
The particle size of the filler ingredient(s) is/are typically in the range of 0.01-50 um. 
Veličina cestica sastojka(aka) je tipično u rasponu od 0.01-50 um.
By empirical testing and calibration, the amount of throughput of mixture from bottle 20 to nozzle 12 can be correlated with the voltage reading of motor 42. 
Empiriskim ispitivanjem 1 kalibriranjem može se veličina protoka mješavine iz boce 20 do mlaznice 12 povezati s naponom u motoru 42.
providing an oligosaccharide comprising a first reactive group, wherein the oligosaccharide is 
osiguravanje oligosaharida koji sadrži prvu reaktivnu skupinu, pri čemu oligosaharid je [image] ili [image]
and R5 are independently selected from H, fluoro or chloro; 
R*i R* su neovisno odabrani od H, fluoro ili kloro;
An immortalized human blood cell of myeloid leukaemia origin capable of producing an antibody molecule composition having the following glycosylation characteristics: it comprises no detectable NeuGc; 
Imortalizirana stanica iz ljudske krvi podrijetlom iz mijeloidne leukemije, naznačena time što može proizvoditi pripravak s molekulom protutijela koja ima sljedeće značajke glikoziliranja:
Use of a compound according to claim 1, wherein the disease is selected from the group consisting of Parkinson's Disease, Alzheimer's Disease, Huntington's disease, epilepsia, cerebral ischemia, haemorrhagic stroke, neonatal ischemia and hypoxia, subarachnoid haemorrhage, traumatic brain injury, brain damage following cardiac arrest, and for the treatment of depression and psychosis disorders. 
Upotreba spoja, koji je dan patentnim zahtjevom 1, naznačena time, da se koristi u slučajevima kada je bolest odabrana unutar skupine koja sadržava Parkinsonovu bolest, Alzheimerovu bolest, Hungtingtonovu bolest, epilepsiju, moždanu ishemiju, hemoragijski udar, neonatalnu ishemiju i hipoksiju, subarahnoidno krvarenje, traumatsko oštećenje mozga, moždano oštećenje kao posljedica srčanog udara, i za tretman depresije u psihotičnih poremećaja.
X is an anion selected from the group consisting of chloride, bromide, iodide, sulphate, phosphate, methanesulphonate, nitrate, maleate, acetate, benzoate, citrate, salicylate, fumarate, tartrate, dibenzoyltartrate, oxalate, succinate, benzoate and p-toluenesulphonate; preferably chloride or dibenzoyltartrate j is 0, 0.5, 1, 1.5 or 2; preferably 1 or 2; with a co-crystal former selected from the group consisting of orotic acid, hippuric acid, L-pyroglutamic acid, D-pyroglutamic acid, nicotinic acid, L-(+)-ascorbic acid, saccharin, piperazine, 3-hydroxy-2-naphtoic acid, mucic (galactaric) acid, pamoic (embonic) acid, stearic acid, cholic acid, deoxycholic acid, nicotinamide, isonicotinamide, succinamide, uracil, L-lysine, L-proline, D-valine, L-arginine, glycine, preferably ascorbic acid, mucic acid, pamoic acid, succinamide, nicotinic acid, nicotinamide, isonicotinamide, l-lysine, l-proline, 
R? je H, C,<-alkil; X je anion odabran iz skupine koju čine klorid, bromid, jodid, sulfat, fosfat, metansulfonat, nitrat, maleat, acetat, benzoat, citrat, salicilat, fumarat, tartrat, dibenzoiltartrat, oksalat, sukcinat, benzoat i p-toluensulfonat; jje 0, 0,5, 1, 1,5 1li 2; s tvorcem ko-kristala koji je odabran iz skupine koju čine orotička kiselina, hipurična kiselina, L-piroglutaminska kiselina, D-piroglutaminska kiselina, nikotinska kiselina, L-(+)-askorbinska kiselina, saharin, piperazin, 3-hidroksi2-naftalinska kiselina, mucinska (galaktarinska) kiselina, pamoična (embonička) kiselina, stearinska kiselina, kolinska kiselina, deoksikolinska kiselina, nikotinamid, izonikotinamid, sukcinamid, uracil, L-lizin, L-prolin, Dvalin, L-arginin, glicin.
identifying cancer specific somatic mutations in a tumor specimen of a cancer patient to provide a cancer mutation signature of the patient; and 
(aa) identificiranje za rak specifičnih somatskih mutacija u uzorku tumora pacijenta oboljelog od raka da bi se osigurala mutacijska signatura raka pacijenta; 1
adding the stabilizer mannitol to an aqueous solution of a cephalosporin derivative; and 
(a) dodavanja manitola kao stabilizatora u vodenu otopinu cefalosporinskog derivata; i
providing strands of wood, and then 
pribavljanje drvenih vlakana i potom
A method according to any of the claims 1 to 9, wherein the provision of a fiber cement product comprising at least one profiled surface comprises the provision of a green fiber cement plate using a Hatschek process, and profiling at least one surface of said fiber cement plate after curing of the green fiber cement plate. 
Postupak prema bilo kojem od patentnih zahtjeva 1 do 9, naznačen time što osiguravanje vlaknastog cementnog proizvoda koji sadrži najmanje jednu profiliranu površinu obuhvaća osiguravanje ploče od zelenog vlaknastog cementa uporabom Hatschekovog postupka, 1 profiliranje najmanje jedne površine navedene ploče od vlaknastog cementa nakon stvrdnjavanja zelene ploče od vlaknastog cementa.
During the third treatment period, the IL-23 antagonist may be administered at the same dose and interval as in the second treatment period or may be administered at a lower dose and/or less frequent interval than used in the previous period. 
IL-17 antagonist za uporabu u skladu sa zahtjevom 20, naznačen time, da navedeno liječenje nadalje obuhvaća primjenu IL-23 antagonista za vrijeme trećeg razdoblja liječenja koje započinje završetkom drugog razdoblja liječenja. 23.
The method as claimed in claimed 1, wherein, a procedure of whitening (35) is subsequently proceeding after said procedure of thread formation (34) for retrieving primary color of said raw austenite 300 series materials. 
Postupak prema zahtjevu 1, naznačen time što postupak izbjeljivanja (35) slijedi nakon spomenutog postupka oblikovanja navoja (34) radi dobivanja prvotne boje sirovog materijala austenita serije 300
wherein each diffractive optical element comprises grooves and a grating vector in the plane of the grooves, having a direction that is normal to the grooves and a magnitude which is inversely related to the pitch of the grooves, wherein the input and output diffractive optical elements respectively have grating vectors with a substantially equal magnitude, 
Optički uređaj u skladu s patentnim zahtjevom 1, naznačen time što svaki difraktivni optički element (17; H0; H1; H2) ima žljebove i vektor rešetke u ravnini žljebova, sa smjerom okomitim u odnosu na žljebove i veličinom obrnuto proporcionalnom nagibu žljebova, gdje ulazni i izlazni difraktivni optički elementi odgovarajuće imaju vektore rešetke uglavnom jednakih veličina.
The method of Claim 8 wherein the environment is soil and a liquid composition comprising the mixture is applied to the soil as a soil drench. 
Metoda iz bilo kojeg od patentnih zahtjeva 1 do 3, gdje je okoliš tlo i tekući se sastav koji obuhvaća smjesu primjenjuje na tlo kao kvašenje tla.
a topcoat being in contact with the absorptive layer, wherein the topcoat has a permeability of greater than 5.0×10-18 m2, wherein the topcoat comprises calcium carbonate. 
završni premaz u doticaju s apsorpcijskim slojem, pri čemu završni premaz ima propusnost veću od 5.0×10-18 m2.
A pharmaceutical composition according to claim 4, that further comprises as active ingredient one or both of mometasone furoate and glycopyrrolate. 
Farmaceutski sastav prema zahtjevu 11, naznačen time, da kao aktivni sastojak, nadalje obuhvaća jedan od spojeva ili oba spoja mometason furoata i glikopirolata,
An apparatus as claimed in claim 1, wherein the expansion turbine (4) comprises a diffuser (27) placed at a position radially external to the stator blades (24a, 24b, 24c) and rotor blades (22a, 22b, 22c). 
Uređaj u skladu s patentnim zahtjevom 1, naznačen time što ekspanzijska turbina (4) sadrži difuzor (27), koji se nalazi na položaju radijalno s vanjske strane u odnosu na lopatice statora (24a, 24b, 24c) i lopatice rotora (224, 22b, 22c).
A process to prepare a compound according to claim 1 characterized by reacting an intermediate of formula (IIa) or (IIb) with an intermediate of formula (III) according to the following reaction scheme 
Postupak za dobivanje spoja prema zahtjevu 1 naznačen time da se sastoji od a) reakcije intermedijera sa formulom (Ila) ili (IIb) sa intermedijerom sa formulom (III) prema slijedećoj reakcijskoj shemi
The method according to claim 12, wherein the material is spread by coating and/or spraying and/or dipping and/or smoothing and/or painting. 
Uporaba materijala za obradu površina sukladno bilo kojem od patentnih zahtjeva 12 do 14 je naznačena time da je taj materijal nanesen premazivanjem i/ili prskanjem i/ili potapanjem i/ili uglačavanjem 1/ili bojanjem.
This was extracted with EtOAc (3×50 mL). 
Ovo je ekstrahirano sa EtOAc (3 X 50 mL).
A lighting module of claim 1, wherein said module circuit is electrically coupled to said conductive housing. 
Rasvjetni modul iz patentnog zahtjeva 16, naznačen time, da je navedeni sklop modula električno priključen na navedeno provodno kućište.
The method of one of claims 26 to 32, wherein the method further comprises: transmitting, in a first-in-time OFDM symbol of said first or second downlink subframe, downlink control signalling in first subcarriers of said First-in-time OFDM symbol and dedicated user data in second subcarriers of said First-in-time OFDM symbol. 
slanje, u prvom po redu OFDM simbolu navedenog prvog ili drugog polukadra silazne veze, kontrolnog signaliziranja silazne veze u prvim podnosiocima navedenog prvog po redu OFDM simbola i namjenskih podataka o korisniku u drugim podnosiocima navedenog prvog po redu OFDM simbola.
A method to mitigate the consequences of an unconfined or partially confined vapor cloud explosion due to the accidental release of a flammable gas in an open area, wherein: 
HR P20170425 T1 PATENTNI ZAHTJEVI Postupak za ublažavanje posljedica neograničene eksplozije oblaka pare zbog slučajnog ispuštanja plina u otvorenom prostoru, naznačeno time da su:
is selected from the group consisting of hydrogen, and methyl; and 
Ru je odabran iz skupine koju čine: vodik i Ci-Cyalkil; i n je 1.
The compound of claim 3 or the use of claim 4, wherein the condition is Type 2 diabetes, Type 1 diabetes, impaired glucose tolerance, hyperglycemia, metabolic syndrome (syndrome X and/or insulin resistance syndrome), glucosuria, metabolic acidosis, arthritis, cataracts, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, diabetic cardiomyopathy, obesity, conditions exacerbated by obesity, hypertension, hyperlipidemia, atherosclerosis, osteoporosis, osteopenia, frailty, bone loss, bone fracture, acute coronary syndrome, short stature due to growth hormone deficiency, infertility due to polycystic ovary syndrome, anxiety, depression, insomnia, chronic fatigue, epilepsy, eating disorders, chronic pain, alcohol addiction, diseases associated with intestinal motility, ulcers, irritable bowel syndrome, inflammatory bowel syndrome; short bowel syndrome; and the prevention of disease progression inType 2 diabetes 
Spoj u skladu s patentnim zahtjevom 3 ili upotreba u skladu s patentnim zahtjevom 4, gdje stanje je dijabetes tipa 2, dijabetes tipa 1, smanjena tolerancija glukoze, hiperglikemija, metabolički sindrom (sindrom X i/ili sindrom otpornosti na inzulin), glukozurija, metabolička acidoza, artritis, katarakta, dijabetička neuropatija, dijabetička nefropatija, dijabetička retinopatija, dijabetička kardiomiopatija, pretilost, stanja čpgoršana pretilošću, hipertenzija, hiperlipidemija, ateroskleroza, osteoporoza, osteopenija, fragilnost, gubitak koštane mase, lomovi kostiju, akutni koronarni sindrom, nizak rast zbog nedostatka hormona rasta, neplodnost zbog sindroma policističnih jajnika, anksioznost, depresija, nesanica, kronična zamorenost, epilepsija, poremećaji hranjenja, kronična bol, ovisnost o alkoholu, bolesti povezane s pokretljivošću crijeva, ulceracije, sindrom iritabilnih crijeva, sindrom crijevne upale; te sprječavanje napredovanja bolesti kod dijabetesa tipa 2.
The membrane 11 is of the type of those available commercially and commonly known by the trade-name Gore-Tex®, optionally coupled to an upper mesh made of synthetic material (not shown in the figures). 
Unutarnji potplat za sklapanje u skladu s patentnim zahtjevom 1, naznačen time, da je navedena membrana (11) spojena na gornju mrežu izrađenu od sintetskih materijala.
The amine used was N,N-dimethylethylenediamine. 
Korišteni amin bio je N,Ndimetiletilendiamin.
In some embodiments, is a single bond and R2 is present. 
U nekim oblicima je jednostruka veza i R> je prisutan.